Introduction {#s1}
============

The modulation of G protein--coupled receptor (GPCR) activity plays an integral role in the treatment of a wide range of diseases. As such, GPCRs have become the target for over one third of current pharmaceuticals, the vast majority of which bind to the orthosteric site of the receptors. This region is defined as the site to which the endogenous ligand(s) for the receptor binds, such as adrenaline for the adrenoceptors or histamine for the histamine receptors ([@B20]; [@B40]; [@B38]). Most clinically used antagonists are orthosteric binders and exert their effects by competitive inhibition. Recently, however, an increasing number of negative and positive allosteric modulators \[negative allosteric modulators (NAMs) and positive allosteric modulators (PAMs), respectively\] for GPCRs has been described ([@B12]), although to date only two have reached the clinic ([@B10]; [@B21]). Rather than directly stimulating or inhibiting biologic effects on their own, these allosteric compounds exert their effects by modulating receptor responsiveness to endogenous agonists. Such allosteric ligands offer a number of potential advantages as drugs, including greater specificity among closely related receptor subtypes, and maximum or ceiling effects that can reduce adverse actions, among others ([@B42]; [@B8]). Such allosteric modulators can also serve as valuable reagents in the research laboratory, where, by means of their cooperative interactions with orthosteric ligands, they can help to freeze or lock specific receptor conformations so that they can be studied by biophysical techniques ([@B8]; [@B38]).

Selection of allosteric modulators for GPCRs using the usual cell-based functional assays such as those for cAMP generation or *β*-arrestin2 (a.k.a. arrestin3) recruitment ([@B28]) has a number of disadvantages. These include that they can be quite laborious and difficult to interpret because one is looking for modulation of a response rather than the on or off responses that such assays are better suited to measure. Such assays are also subject to a variety of artifacts and have relatively limited compounds throughput of ∼10^3^--10^6^. In contrast, interaction or affinity-based methods, in which large libraries of self-encoding potential binders are screened against a target protein molecule, circumvent these shortcomings. A particularly powerful approach is the use of DNA-encoded small-molecule libraries (DELs) potentially containing billions of compounds. Each molecule in such a library is covalently linked to a small stretch of nucleotides, which serves as a barcode that is used to identify target binders by next-generation sequencing (NGS) ([@B11]; [@B13]). Such approaches work well when applied to soluble protein targets but have been much more difficult to adapt to membrane proteins such as GPCRs. However, using this approach, we recently described isolation of the first NAM for the *β*~2~-adrenoceptor (allosteric β-blocker) ([@B1]) and identified its intracellular binding site on the receptor by X-ray crystallography ([@B22]). This molecule, compound (Cmpd)-15, was isolated by panning DELs against the inactive receptor, in which the orthosteric site was unoccupied.

An advantage of affinity-based screening methods is that one can bias the selections toward isolation of molecules with a particular functional profile by including one or another orthosteric ligand or even allosteric transducer protein molecules, e.g., G protein or *β*-arrestin, in complex with the receptor. In this work, we report our successful isolation of the first PAMs of the *β*~2~-adrenoceptor (*β*~2~AR) by panning DELs against the purified receptor occupied by the high-affinity agonist BI-167107 ([@B29]). We present a detailed pharmacological characterization of these molecules with the receptor and illustrate their potential utility as laboratory tools for interrogating biophysical properties of the receptors, as well as molecules for a new type of therapeutic agent.

Materials and Methods {#s2}
=====================

 {#s3}

### Materials. {#s4}

Cmpd-6 and its analogs were synthesized using the methods described below. With the exception of BI-167107, which was synthesized as described previously ([@B39]), all of the orthosteric *β*~2~AR ligands used were purchased from Sigma-Aldrich (St. Louis, MO) and sourced at a 95% or greater purity. Nuevolution provided the DNA-encoded libraries used for screening. The \[^3^H\](*R*,*R′*)-4-methoxyfenoterol used in the radioligand-binding studies was provided by Irving Wainer (Laboratory of Clinical Investigation, National Institute on Aging Intramural Research Program, Bethesda, MD). The *β*~2~AR-Gs*α* and *β*~2~ vasopressin 2 receptor (V~2~R)-*β*-arrestin1 fusion clones containing an N-terminal hemagglutinin signal sequence followed by a FLAG epitope tag for the receptor were generated in pcDNA3.1 by standard polymerase chain reaction (PCR) amplification and cloning procedure. *β*-arrestin1 cDNA was amplified by standard PCR methods and cloned in-frame with the C terminus of *β*~2~V~2~R essentially as before ([@B35]). For the Gs fusion construct, the coding sequence for the short splice variant of human Gs*α* subunit was used from a plasmid obtained from cDNA Resource Center (Bloomsburg, PA). Both Gs*α* and *β*~2~AR sequences were PCR amplified separately, and the amplified fragments were assembled into a tetracycline-inducible pcDNA3.1 plasmid by using HiFi DNA assembly (NEB, Ipswich, MA) to finally generate the Gs*α* fusion at the C terminus of the receptor. Both fusion constructs were sequence verified, and aliquots of maxi-prepared DNA were used for transfections. Previous purification methods were used to obtain rat *β*-arrestin1 (a nonvisual arrestin, a.k.a. arrestin2) and heterotrimeric Gs protein ([@B32]; [@B33]).

### Cell Culture and Transfection. {#s5}

HEK-293 and HEK-293T cells were cultured at 37°C and at 5% CO~2~ in a humidified condition. Cells were cultured in standard minimum Eagle's growth media supplemented with 10% fetal bovine serum and penicillin/streptomycin. HEK-293 cell lines stably expressing the GloSensor (Promega, Madison, WI) cAMP reporter ([@B25]) and HEK-293T cells for the Tango assay ([@B3]) were maintained, as described before. The HEK-293 cell line stably expressing the GloSensor cAMP reporter together with the *β*~2~AR was created by transfecting a hygromycin B--resistant plasmid expressing the GloSensor reporter into cells stably overexpressing the *β*~2~AR ([@B31]), followed by selection with 150 *μ*g/ml hygromycin B (Invitrogen, Carlsbad, CA). The clonal line with the greatest fold over basal ratio and highest sensitivity was selected and maintained with 150 *μ*g/ml G418 (Sigma-Aldrich) and 100 *μ*g/ml hygromycin B. Transient transfections were performed using FuGENE 6 (Promega), according to the manufacturer's instructions, and all assays were done ∼48 hours post-transfection. The *β*~2~AR-Gs and *β*~2~V~2~R-*β*-arrestin 1 fusion proteins were transfected into Expi293F cells (Invitrogen) using Expifectamine (Invitrogen), as described by the manufacturer.

### Expression, Purification, and High-Density Lipoprotein Reconstitution of the *β*~2~AR. {#s6}

As previously described ([@B16]), BestBac Baculovirus Expression System was used to express the full-length human *β*~2~AR containing an amino-terminal FLAG epitope tag, carboxyl-terminal His-tag, and a N187E glycosylation mutation in Sf9 insect cells. In brief, cells were infected at a density of 3 × 10^6^ cells/ml and harvested 67 hours thereafter. The cells were then solubilized in a buffer containing 1% *n*-dodecyl-*β*-[d]{.smallcaps}-maltoside (Anatrace, Maumee, OH), 20 mM HEPES, pH 7.4, 150 mM NaCl, and protease inhibitors. Functional *β*~2~AR was purified, as previously described ([@B16]; [@B15]), using FLAG-M1 antibody and alprenolol affinity chromatography, followed by size exclusion chromatography using a Superdex 200 (16/600 prep grade) column. The monomeric receptor peak from the size exclusion chromatography was pooled and concentrated to 1--2 mg/ml. Purified functional *β*~2~AR was then reconstituted into high-density lipoprotein (HDL) particles using previously published methods ([@B41]; [@B33]). In brief, FLAG-*β*~2~AR was incubated with a 50-fold molar excess of biotinylated membrane scaffold protein 1 Apo A1 and 8 mM POPC:POPG (3:2 molar ratio; 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine and 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phospho-\[1′-rac-glycerol\]) lipids (Avanti Polar Lipids, Alabaster, AL) for 1 hour at 4°C. Detergent was removed using BioBeads SM-2 (Bio-Rad, Hercules, CA) by incubating overnight at 4°C. Then, receptor-containing HDL particles were isolated using FLAG-M1 affinity chromatography and size exclusion chromatography.

### DNA-Encoded Small-Molecule Library. {#s7}

The DNA-encoded small-molecule libraries used for screening were created using a tagged-split-and-pool chemistry approach (Chemetics) at Nuevolution, as previously described ([@B17]).

### Affinity Selection. {#s8}

[Figure 1A](#F1){ref-type="fig"} schematically illustrates the library selection process. More specifically, 30 *μ*g biotinylated *β*~2~AR-HDL particles were immobilized on 25 *μ*l NeutrAvidin beads (Thermo Fisher Scientific, Waltham, MA). The *β*~2~ARs bound to NeutrAvidin beads were then incubated with library molecules in 50 *μ*l binding buffer (20 mM HEPES, pH 7.4, 100 mM NaCl) supplemented with 20 *μ*M BI-167107 (BI) and 1 mg/ml sheared salmon sperm DNA (ssDNA; Ambion, Waltham, MA) for 45 minutes at room temperature, while intensely shaken. Prior to this incubation, 1 *μ*l library molecules were allocated for later quantitative PCR (qPCR). Following this incubation, the beads were transferred to a micro-column connected to a vacuum apparatus and subsequently washed three times with 100 *μ*l ice-cold binding buffer containing 10 *μ*M BI. During each of the washing steps, excess liquid was removed via vacuum suction. To elute off the bound compounds, the beads were incubated twice with 50 *μ*l water containing 1.5% Fos-choline (Avanti Polar Lipids) at 37°C for 15 minutes and subsequently at 72.5°C for 15 minutes. Following this incubation, the solution was separated from the beads by centrifugation at 1000 × g for 1 minute. After addition of 1 *μ*l 10 mg/ml ssDNA, the combined supernatant was applied to a nucleotide removal kit (Qiagen, Hilden, Germany) to remove denatured protein and lipid molecules. The mixture of the bound compounds was then eluted with 50 *μ*l water from the nucleotide removal column, and 1 *μ*l purified material was allocated for later qPCR quantification. The remaining purified sample was then either used for the next round of selection with fresh *β*~2~AR-HDLs, or applied to NGS.

![Hit compounds from DEL screening with the agonist-occupied *β*~2~AR in HDL particles. (A) Cartoon for DEL screening. Purified human *β*~2~ARs were reconstituted in HDL particles (*β*~2~AR Nanodiscs) and then occupied by BI-167107 (BI). DNA-encoded library molecules were mixed with the BI-occupied *β*~2~AR Nanodiscs immobilized on NeutrAvidin beads through biotin--avidin interaction of biotinylated membrane scaffolding protein ApoA1. Three rounds of iterative selection were performed with each library. (B) Structures of the Cmpd-6 and six other primary hits. These compounds have varied chemical scaffolds in a common region, designated as R1. The different chemical structures in the R1 region of each analog are illustrated. (C) Analysis of Cmpd-6 for its physical interaction with the agonist-bound, active *β*~2~AR by ITC. The thermogram (insert) and binding isotherm with the best titration curve fit are shown. One site model was used to fit the data. Data are representative of three independent experiments. The values summarizing binding affinity (K~D~), stoichiometry (N), enthalpy (ΔH), and entropy (ΔS) are shown in box below the graph.](mol.118.111948f1){#F1}

### Quantitative PCR. {#s9}

Library DNA was quantified using qPCR at the end of each round of affinity selection. Briefly, the DNA samples were either directly amplified, or amplified after being diluted in solution containing 0.1% Tween 20, 20 mg/mL ssDNA using JumpStart Taq ReadyMix (Sigma-Aldrich), according to manufacturer's guidelines. The samples from the libraries before selection were evaluated using at least four different concentrations on a log scale. This provides a standard to determine the DNA copy number of the samples from each iterative round of selection. The reaction was done with the primer set, including the universal forward primer (5′-CAAGTCACCAAGAATTCATG-3′) and a unique reverse primer for each library, and FAM/TAMRA probe 5′-CAGACGACCTAGGATCACC-3′ using a StepOnePlus (Applied Biosystems, Waltham, MA).

### NGS and Analysis. {#s10}

To increase the yield and then append the required sequencing adapters for emulsion PCR, the affinity-selected materials were amplified by two rounds of PCR. The first round of PCR was done with the same oligonucleotide primer set as used for qPCR. The second round of PCR was performed with oligonucleotide primers made from fusing the Ion Torrent adapter sequences to the universal forward primer, to which a sorting code was inserted to allow for sample pooling, and a unique reverse primer for each library. The unique sequence of the reverse primer provides precise sample tracking and a distinct identifier for each library. Following gel purification, the final PCR products were subjected to single-direction amplicon sequencing using the Ion Torrent platform (PrimBio, Exton, PA). Sequences having significant copy numbers (high signal-to-noise ratio), determined by analyzing the NGS output using a custom-built algorithm, were deconvoluted to their corresponding chemical structures from the database.

### Isothermal Titration Calorimetry. {#s11}

Isothermal titration calorimetry (ITC) experiments were performed with maltose neopentyl glycol (MNG; Anatrace)--solubilized *β*~2~AR on a MicroCal Auto-iTC200 system (Malvern, Malvern, UK), according to the previously reported method ([@B1]). Dialysis of the purified *β*~2~AR was carried out against a dialysis buffer (20 mM HEPES, pH 7.5, 100 mM NaCl, 0.01% MNG, and 0.001% cholesteryl hemisuccinate). Titrations were performed at 25°C, in which 40 *μ*l 200 *μ*M Cmpd-6 in the aforementioned dialysis buffer was loaded into the syringe, followed by an initial injection of 0.2 *μ*l, and then subsequent 2 *μ*l injections (0.4-second duration, 150-second spacing, and 5-second filter period) into the 200 *μ*l sample cell containing *β*~2~AR (at 30 *μ*M final) prestimulated with isoproterenol (ISO; 2 mM final). During the experiment, the reference power was set to 7 *μ*cal × s^−1^ and sample cell was stirred continuously at a speed of 1000 rpm. ITC raw data were baseline corrected, peak area integrated, and fitted by using a one-site nonlinear least-squares fit model using the MicroCal Origin software program, to provide affinity constant (KD), stoichiometry (N), and thermodynamic parameters such as enthalpy (ΔH) and entropy (ΔS).

### Radioligand Binding. {#s12}

Binding experiments were done as previously detailed ([@B1]). In brief, competition radioligand binding was done using the radiolabeled antagonist \[^125^I\]-cyanopindolol (CYP; 2200 Ci/mmol; PerkinElmer, Waltham, MA) at a concentration of 60 pM. The *β*~2~AR-HDL particles were used at ∼0.7 ng per reaction. Reactions consisted of the *β*~2~AR-HDL particles, ^125^I-CYP, Cmpd-6 at varying concentrations, and a serial dilution of a competitor *β*~2~AR agonist, most often ISO. All of the components were diluted in an assay buffer \[20 mM HEPES, pH 7.4, 100 mM NaCl, 0.1% bovine serum albumin (BSA), and 1 mM ascorbic acid\]. Each reaction was allowed to reach equilibrium by incubating for 90 minutes at room temperature. Assays were then terminated by rapid filtration onto GF/B glass-fiber filters (Brandel, Gaithersburg, MD) treated with 0.3% polyethyleneimine and washed with 8 ml cold binding buffer (20 mM HEPES, pH 7.4, 100 mM NaCl) using a harvester (Brandel). ^125^I-CYP bound to the *β*~2~AR-HDL particles was measured using either a Packard Cobra Quantum gamma counter (Packard; GMI, Ramsey, MN) or a WIZARD2 2-Detector Gamma Counter (PerkinElmer). Data were expressed as specific binding.

For \[^3^H\]-methoxyfenoterol (^3^H-FEN) ([@B37]) binding, membrane preparations from Sf9 cells expressing either *β*~2~AR or *β*~2~V~2~R were used. For in cell phosphorylation of *β*~2~V~2~R, GRK2-CAAX was coexpressed and, prior to harvest, cells were stimulated with the agonist ISO (10 *µ*M) for 20 minutes. Membranes for *β*~2~AR and phosphorylated *β*~2~V~2~R were essentially prepared, as described earlier ([@B35]; [@B1]). For ^3^H-FEN binding with Gs or nanobody-80 (Nb80), *β*~2~AR membranes were incubated in the G protein assay buffer (50 mM Tris-HCl, pH 7.4, 2 mM EDTA, 12.5 mM MgCl~2~). For binding assays containing rat *β*-arrestin1, phosphorylated *β*~2~V~2~R membranes were incubated in the *β*-arrestin assay buffer (50 mM Tris-HCL, pH 7.4, 50 mM potassium acetate, 5 mM MgCl~2~). Both assay buffers were supplemented with 0.05% BSA and 0.018% L-ascorbic acid. ^3^H-FEN (12.6 Ci/mmol) was used at its K-hi (4.3 nM) in binding assays testing for PAM activity of Cmpd-6 (and its analogs) and Cmpd-43. In ^3^H-FEN saturation-binding assays, testing for the cooperativity of Cmpd-6 (20 *µ*M) with Gs (100 nM), *β*arr1 (1 *µ*M), or Nb80 (1 *µ*M), ^3^H-FEN was used in the range of 0.39--50 nM to saturate the high-affinity agonist binding sites in the receptor. All binding reactions were incubated to equilibrium (90 minutes) at room temperature and then harvested onto polyethyleneimine-soaked GF/B filters, followed by four rapid washes of 2 ml with prechilled G protein wash buffer (50 mM Tris-HCl, pH 7.4, 2 mM EDTA, 12.5 mM MgCl~2~) or *β*-arrestin wash buffer (50 mM Tris-HCL, pH 7.4, 50 mM potassium acetate). Bound \[^3^H\] was extracted overnight with 5 ml scintillation fluid and quantified using a Packard Cobra Quantum gamma counter (Packard; GMI). Nonspecific radioligand binding was assessed in reactions that contained the antagonist propranolol (20 *µ*M).

### Measurements of cAMP Production. {#s13}

cAMP production, an indirect marker of Gs protein activation, was measured using the GloSensor (Promega), a chemiluminescence-based cAMP biosensor, as previously described ([@B1]). In brief, HEK-293 cells stably expressing the GloSensor luciferase enzyme alone, or together with the *β*ARs, were plated in 96-well, white clear-bottom plates at a density of ∼80,000 cells/well. Cells were given at least a 24-hour incubation to recover cell surface receptor expression before the assay was started. Cells were then treated with the GloSensor reagent (Promega) and incubated at 27°C and ∼100% relative humidity for ∼1 hour. Cells were then treated with either a varying dose of Cmpd-6 or a vehicle control \[dimethylsulfoxide (DMSO)\] diluted in Hanks' balanced solution (Sigma-Aldrich), supplemented with 20 mM HEPES, pH 7.4, 0.05% BSA, and 3-isobutyl-1-methylxanthine (Sigma-Aldrich) at a final concentration of 100 *μ*M. For most of the cAMP assays, cells were then incubated further for 20 minutes, before a serial dilution of the *β*-agonist was added. For the assays with HEK-293 cells stably overexpressing *β*~2~AR, Cmpd-6 and the *β*-agonist serial dilution were added to the cells simultaneously. Upon stimulation of the cells with the *β*-agonist, changes in luminescence were read using a NOVOstar microplate reader (BMG Labtech, Cary, NC) at various time points ranging from 5 to 35 minutes.

### Measurement of *β*-Arrestin Recruitment. {#s14}

*β*-arrestin2 recruitment to the receptor was measured using the previously described Tango assay ([@B3]). HEK-293T cells stably expressing the *β*~2~V~2~R tethered to the tetracycline transactivator transcription factor by a tobacco etch virus protease cleavage site, the human *β*-arrestin2 protein fused to the tobacco etch virus protease, and the tetracycline transactivator--driven luciferase reporter were used for this assay. Cells were plated on a 96-well, white clear-bottom plate at a density of ∼50,000 cells/well and were given at least a 24-hour incubation at 37°C, 5% CO~2~, and ∼100% relative humidity to recover surface receptor expression. Cells were treated with either a varying dose of Cmpd-6 or a vehicle control (DMSO) diluted in Hanks' balanced solution (Sigma-Aldrich), supplemented with 20 mM HEPES, pH 7.4, and 0.05% BSA, and then incubated at 37°C, 5% CO~2~, and ∼100% relative humidity for ∼20 minutes. After the incubation, a serial dilution of the *β*-agonist was added, following which the cells were incubated for 6 hours at 37°C and ∼100% relative humidity. At the end of the incubation, the plate was cooled to room temperature. After adding the Bright-Glo reagent (Promega), chemiluminescence signals were read using a NOVOstar microplate reader (BMG Labtech) at 5--10 minutes.

### Bimane Assay. {#s15}

The minimal cysteine *β*~2~AR ([@B44]) was used in bimane fluorescence experiments. For bimane labeling at cysteine-265 of the *β*~2~AR, threefold molar excess of monobromobimane (Sigma-Aldrich) was used, as previously described ([@B44]), and HDL reconstitution of the *β*~2~AR-bimane was carried out, as described above. Bimane-labeled *β*~2~AR-HDLs at 250 nM were incubated in black, solid-bottom 96-well microplates with the vehicle (DMSO) or 10 *μ*M ISO, either alone or together with 1 *μ*M Nb80 or 20 *μ*M Cmpd-6 for 30 minutes at room temperature. All of the components were diluted in buffer comprised of 20 mM HEPES, pH 7.4, and 100 mM NaCl. A CLARIOstar plate reader (BMG Labtech) was used to collect fluorescence emission spectra using the top-read mode with excitation at 370 nm (16-nm bandpass) and emission scanning from 400 to 600 nm (10 nm bandpass) in 1-nm increments.

### Nanobody Enzyme-Linked Immunosorbent Assay. {#s16}

As previously described, the 6X-His tagged nanobodies, Nb80 ([@B29]) and Nb6B9 ([@B30]), were purified from periplasmic extracts of *Escherichia coli* WK6 cells. Nanobodies were affinity purified using Ni-NTA agarose beads (Qiagen). Purified nanobodies were then dialyzed overnight in 20 mM HEPES, pH 7.4, 100 mM NaCl, followed by size-exclusion chromatography. Nb80 (10 *µ*g/ml) was passively adsorbed onto Maxisorp (NUNC, Roskilde, Denmark) 96-well plates (Thermo Fisher Scientific, St. Louis, MO) in nanobody buffer (20 mM HEPES, pH 7.4, 100 mM NaCl), and plates were incubated overnight at 4°C. Enzyme-linked immunosorbent assay was performed essentially as described before ([@B34]). Purified *β*~2~AR was preincubated with 0.2% DMSO or 10 *µ*M final of either ICI-118551 or BI-167107 ligands, and Cmpd-6 (20 *µ*M) or Nb6B9 (1 *µ*M) for 30 minutes in assay buffer (20 mM HEPES, pH 7.4, 100 mM NaCl) containing 0.01% MNG (Anatrace), 0.001% cholesteryl hemisuccinate (Sigma-Aldrich), and 0.5% BSA. The preincubated reactions were then overlaid on Nb80-adsorbed 96-well plates for 90 minutes at room temperature. Following incubation, the unbound material was washed with assay buffer, and the captured *β*~2~AR was detected using a horseradish peroxidase--conjugated anti-Flag (M2) antibody (1:5000) diluted in assay buffer. Following antibody incubation (1 hour, room temperature), plates were washed with assay buffer, and signal was developed using 100 *µ*l Ultra-TMB (Pierce, Rockford, IL). The developed signal was quenched with 100 *µ*l acidified assay buffer, and the absorbance was measured at 450 nm.

### Synthesis and Characterization of Cmpd-6 and Its Derivatives. {#s17}

Complete details of chemical syntheses are described in [Supplemental Material](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1).

Results {#s18}
=======

 {#s19}

### Screening and Identification of Primary Hits Including Cmpd-6 and -43. {#s20}

Using our recently developed approach for screening DELs against GPCRs ([@B1]), in this study we screened ∼500 million unique DNA-encoded small molecules ([Supplemental Table 1](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)) to obtain PAMs at the *β*~2~AR. To increase the chance of obtaining PAMs, the orthosteric site of the receptor was occupied by a high-affinity *β*-agonist BI-167107, which shifted the *β*~2~AR population toward active conformations ([@B29]; [@B23]) ([Fig. 1A](#F1){ref-type="fig"}). Furthermore, purified human *β*~2~ARs were reconstituted in detergent-free HDL particles ([Fig. 1A](#F1){ref-type="fig"}). The HDL reconstitutions were performed using a biotinylated version of the membrane scaffolding protein ApoA1 ([@B41]). In addition to providing the receptor with a native-like membrane environment, the biotinylated HDL particles provide an excellent immobilization scheme that avoids any physical perturbations to the receptor during the screening process. The *β*~2~ARs in biotinylated HDL particles can be efficiently captured on NeutrAvidin beads ([Supplemental Fig. 1A](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)) and have a comparable affinity for antagonist binding to that of *β*~2~ARs in membrane preparations ([Supplemental Fig. 1B](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)). Furthermore, by competitive radioligand-binding assays, we show that *β*~2~ARs in HDL particles can functionally couple to heterotrimeric Gs ([Supplemental Fig. 1C](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)). G protein coupling to the *β*~2~AR substantially increases the affinity of the competing agonist---ISO. This high-affinity coupling of Gs to the *β*~2~AR can be completely blocked by the addition of GTP*γ*S---a nonhydrolyzable GTP analog.

Using the BI-167107--occupied *β*~2~AR in HDL particles, we iteratively screened four different DELs ([@B17]), each of which comprised over 100 million unique compounds ([Supplemental Table 1](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)), to isolate molecules that specifically bound to the active state of the receptor. The total number of molecules in each library was ∼0.5--1 × 10^14^. Three rounds of iterative selection ([Fig. 1A](#F1){ref-type="fig"}) were performed with each library until the total number of target-bound molecules was decreased to ∼1 × 10^6^, which was monitored by qPCR. Following amplification of preserved DNA barcodes by PCR, the samples were subjected to NGS to identify compounds that outlasted the entire selection procedure. Sequences having significant copy numbers (i.e., high signal-to-noise ratio) were deconvoluted to their corresponding chemical structures from the database. Through this analysis, we determined 50 compounds as primary candidates that possibly bind to the *β*~2~AR ([Supplemental Table 1](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)) and named them Cmpd-1 to Cmpd-50. These 50 candidate compounds were synthesized on a small scale without their DNA barcodes to evaluate their activity as PAMs in secondary screens.

PAMs are expected to potentiate the binding of orthosteric agonists to GPCRs and even plausibly the coupling of transducer proteins, e.g., G protein and *β*-arrestin, to receptors ([@B42]; [@B8]). Accordingly, these 50 potential hits were tested for their ability to increase the binding of the radiolabeled agonist, ^3^H-FEN ([@B37]), to the *β*~2~AR in membrane preparations, both in the absence and presence of transducers ([Supplemental Fig. 1D](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)). Through this secondary screen, we identified seven structurally related compounds, as shown in [Fig. 1B](#F1){ref-type="fig"}, including Cmpd-6, which showed the strongest PAM activity among the compounds ([Supplemental Fig. 1E](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)). These compounds not only increased ^3^H-FEN binding to the *β*~2~AR alone, but also, to varied extents, potentiated the transducer-induced high-affinity ^3^H-FEN binding at the receptor. Interestingly, between these compounds, only subtle structural differences were observed, which were confined to one variable region designated as R1 (blue colored in [Fig. 1B](#F1){ref-type="fig"}). Two of the seven compounds (Cmpd-6 and -43) were chosen for further characterization of their PAM activity and were synthesized on a large scale.

To assess direct molecular interaction between Cmpd-6 and the agonist-bound, active *β*~2~AR, ITC was employed. The values summarizing binding affinity (K~D~), stoichiometry (N), and thermodynamic parameters are shown in [Fig. 1C](#F1){ref-type="fig"}. ITC values indicate that the process of interaction between Cmpd-6 and active *β*~2~AR is exothermic, therefore enthalpically favored with a stoichiometry of ∼1 and K~D~ of 5.2 ± 0.5 *μ*M.

### PAM Activity of Cmpd-6 and -43 in *β*~2~AR-Mediated Downstream Signaling. {#s21}

To evaluate the PAM activity of Cmpd-6 and -43 in *β*~2~AR-mediated downstream functions, we monitored their effects on both agonist-induced Gs protein--cAMP production ([@B5]; [@B27]) and *β*-arrestin2 recruitment to the receptor ([@B27]; [@B4]) using cellular assays. An issue encountered in these functional assays is the differential levels of the signal produced by virtue of the high amplification process downstream of Gs protein activation, compared with the stoichiometric recruitment of *β*-arrestin2 to the receptor ([@B27]). To circumvent this problem and achieve similar levels of the signal in the two cellular assays, we used the endogenously expressed *β*~2~AR in cAMP production assays, whereas *β*-arrestin2 recruitment was measured using cells stably overexpressing the *β*~2~V~2~R. This chimeric receptor has the V~2~R tail recombinantly appended at the C terminus of the *β*~2~AR, retaining the pharmacological traits of the native *β*~2~AR, but displaying a more stable interaction with *β*-arrestin, which is an advantage for *β*-arrestin recruitment assays ([@B36]). Both Cmpd-6 and -43 increased the ability of the agonist ISO to activate G protein--mediated cAMP production through the *β*~2~AR in a dose-dependent way ([Fig. 2, A and B](#F2){ref-type="fig"}). We observed that Cmpd-6 ([Fig. 2A](#F2){ref-type="fig"}) and Cmpd-43 ([Fig. 2B](#F2){ref-type="fig"}) increased the maximal response induced by ISO, as well as potentiating the EC~50~ value of ISO, which was apparent in its left-shifted dose--response curve. In this assay, Cmpd-6 shows stronger activity than Cmpd-43, which is consistent with the preliminary data showing the extent of dose-dependent increases in ^3^H-FEN binding to the *β*~2~AR induced by these compounds, shown in [Supplemental Fig. 1E](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1). We also obtained a comparable pattern of agonist-induced *β*-arrestin2 recruitment to the *β*~2~V~2~R with Cmpd-6 ([Fig. 2C](#F2){ref-type="fig"}) and Cmpd-43 ([Fig. 2D](#F2){ref-type="fig"}), respectively.

![Activity assays for G protein activation and *β*-arrestin2 recruitment in the presence of Cmpd-6 and -43. Either Cmpd-6 (A and C) or Cmpd-43 (B and D) was pretreated in assay cells for 15--20 minutes at various concentrations, as indicated, and then cells were stimulated with ISO in a dose-dependent manner. (A and B) The amount of cAMP production by the endogenously expressed *β*~2~AR was measured at 15--20 minutes after stimulation with ISO. (C and D) The level of *β*-arrestin2 recruitment to the stably overexpressed *β*~2~V~2~R was measured at 6 hours after stimulation with ISO. Curve fits were generated using the software GraphPad Prism with data points obtained from four (B--D) or five (A) independent experiments done in duplicate. Each data point was normalized to the maximal level of the ISO-induced activity in the vehicle (0.32% DMSO) control, expressed as a percentage, and represents mean ± S.D. The shift of curves was expressed as fold changes in EC~50~ and Bmax values. Statistical analyses for these shifts in each of the directions were performed using one-way analysis of variance, repeated (related) measures with Tukey's multiple comparison post-tests. *P* values shown on each graph were for the curve obtained when compound was pretreated at the highest concentration, compared with the control DMSO curve. Adjusted \*\**P* \< 0.01; \*\*\**P* \< 0.001; \*\*\*\**P* \< 0.0001.](mol.118.111948f2){#F2}

Increases in the ISO-induced maximal response by Cmpd-6 and -43 in both assays suggest that ISO may act as a partial agonist, which does not reach the maximum response possible in these systems ([@B19]), allowing Cmpd-6 and -43 to further increase the maximal agonist-induced response. To verify this, we monitored cAMP production by overexpressed *β*~2~AR (a system that has much higher amplification; [Supplemental Fig. 2](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)) in the presence or absence of Cmpd-6. We observed that Cmpd-6 led to dose-dependent leftward shifts of the ISO dose-response EC~50~ values, with increases in the basal activity, but did not increase the ISO-stimulated maximal response. This shows that even a full agonist such as ISO can act as a partial agonist depending on the assay system used, which would not have been suspected without the cooperativity displayed by these new PAMs. Overall, these results strongly demonstrate that Cmpd-6 and -43 have PAM activity for *β*~2~AR-mediated downstream functions, and that Cmpd-6 has stronger PAM activity than Cmpd-43.

### Cmpd-6 and -43 Potentiate the Binding Affinity of Agonists for the *β*~2~AR. {#s22}

A hallmark of PAMs is that they allosterically stabilize the agonist-bound active conformation of the receptor ([@B19]), as do transducer proteins, G protein and *β*-arrestin, as illustrated in the GPCR ternary complex model ([@B9]). Because PAM-mediated stabilization of active GPCR conformations leads to potentiation of agonist-binding affinity for the receptor, we next tested whether Cmpd-6 and -43 increase the binding of an agonist to the *β*~2~AR. For this, we monitored the competition binding of the orthosteric agonist ISO against the radiolabeled antagonist ^125^I-cyanopindolol (CYP) to the *β*~2~AR-HDL in the presence or absence of Cmpd-6 ([Fig. 3A](#F3){ref-type="fig"}) and Cmpd-43 ([Fig. 3B](#F3){ref-type="fig"}). As expected, both compounds potentiated the binding of ISO to the *β*~2~AR in a dose-dependent way, as evidenced by the robust left shifts in ISO competition curves. Consistent with the results obtained in the cellular assays ([Fig. 2](#F2){ref-type="fig"}), at their highest concentration tested ([Fig. 3, A and B](#F3){ref-type="fig"}), Cmpd-6 potentiated the IC~50~ value of ISO close to 50-fold, which was substantially more than the ∼30-fold change elicited by Cmpd-43. Additionally, we obtained comparable shifts in the ISO dose--response curve induced by Cmpd-6 and -43 in radioligand competition binding done with membranes prepared from *β*~2~AR-overexpressing cells ([Supplemental Fig. 3, A and B](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)).

![Positive allosteric activity of Cmpd-6 and -43 for orthosteric ligand binding to the *β*~2~AR. (A and B) Cmpd-6-- and Cmpd-43--mediated dose-dependent left shifts of the ISO competition curve against ^125^I-CYP binding to the *β*~2~AR. Binding of ^125^I-CYP against ISO in a dose-dependent manner was measured in the absence (DMSO) or the presence of various concentrations of Cmpd-6 (A) or Cmpd-43 (B), as indicated. Curve fits were plotted by a one-site competition-binding log IC~50~ curve fit (GraphPad Prism) with data sets obtained from four independent experiments done in duplicate. Each data point was normalized to the percentage of the maximal ^125^I-CYP binding level obtained from the control (0.64% DMSO-treated) curve and represents mean ± S.D. Statistical analyses for the shift of IC~50~ values were performed using one-way analysis of variance, repeated (related) measures with Tukey's multiple comparison post-tests. *P* values were for the curve obtained when compound was pretreated at the highest concentration, compared with the control DMSO curve. Adjusted \*\*\*\**P* \< 0.0001. (C) Cmpd-6 and -43 dose-dependent increases in ^3^H-FEN binding to the *β*~2~AR. Curve fits were generated using the software GraphPad Prism with data points obtained from six independent experiments. Each data point was normalized to the maximal level obtained in the presence of Cmpd-6 and represents mean ± S.D.](mol.118.111948f3){#F3}

Additionally, results shown in [Fig. 3C](#F3){ref-type="fig"} further confirm the PAM activity of Cmpd-6 and -43 for increasing the binding of an orthosteric agonist to the *β*~2~AR. Cmpd-6 and -43 dose dependently increased the binding of the radiolabeled agonist ^3^H-FEN to the *β*~2~AR expressed in cell membranes, consistent with what we observed in our preliminary experiments with these compounds ([Supplemental Fig. 1E](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)). Again, Cmpd-6 is more efficacious than Cmpd-43 in increasing ^3^H-FEN binding to the *β*~2~AR. Furthermore, the low micro-molar affinity (EC~50~) value of Cmpd-6 obtained in this assay ([Fig. 3C](#F3){ref-type="fig"}) is comparable to its K~D~ value measured for its direct interaction with the *β*~2~AR by ITC analyses ([Fig. 1C](#F1){ref-type="fig"}). We also observed another feature of allosteric molecules, the ceiling effect, with these compounds in both binding experiments ([Fig. 3](#F3){ref-type="fig"}). The increases in the binding of both agonists, ISO ([Fig. 3, A and B](#F3){ref-type="fig"}) and FEN ([Fig. 3C](#F3){ref-type="fig"}), were saturated with increasing concentrations of these allosteric compounds.

### Cmpd-6 Stabilizes the Agonist-Induced Active Conformation of the *β*~2~AR. {#s23}

We further demonstrated that Cmpd-6 stabilizes active conformational ensembles of the *β*~2~AR through a biophysical assay. Agonist-induced activation of the *β*~2~AR causes the outward movement of transmembrane helix 6 (TM6), which can be detected by labeling of cysteine-265 at the intracellular base of TM6 with monobromobimane, an environmentally sensitive fluorescent label. Following receptor activation, the outward movement of TM6 leads to a decrease in fluorescence intensity with a concomitant increase in the maximum wavelength for emission ([@B29]). Cmpd-6 alone induced decreases in overall fluorescence intensity, but not increases in the maximum wavelength for emission from the bimane-labeled *β*~2~AR ([Fig. 4](#F4){ref-type="fig"}). In contrast, ISO decreased fluorescence to a similar extent, but also increased the maximum wavelength. This suggests that the conformational ensemble of the *β*~2~AR when bound to Cmpd-6 alone is similar to, but distinct from, that induced by orthosteric agonists. Interestingly, Cmpd-6 further potentiated ISO-induced decreases in the fluorescence intensity and increases in the maximum wavelength from the bimane-labeled *β*~2~AR ([Fig. 4](#F4){ref-type="fig"}). Importantly, Cmpd-6--mediated potentiation of ISO effects was similar in magnitude to that observed with an allosteric nanobody (Nb80) that mimics the G protein--stabilized active conformation of the agonist-bound *β*~2~AR ([@B29]). These data clearly demonstrate that Cmpd-6 stabilizes active conformations of the agonist-bound *β*~2~AR, engaging the outward movement of TM6 to an extent comparable to that mediated by transducers like G protein.

![Positive allosteric activity of Cmpd-6 in agonist-induced *β*~2~AR bimane signals. (A) The fluorescence emission spectrum of monobromobimane-labeled *β*~2~AR in HDL particles. Data shown are representative of three independent experiments. (B) Bar graph summarizes the analyses, in which normalized peak fluorescence values are expressed relative to DMSO control (0.2%). Values indicate mean ± S.D. Statistical analysis for the results depicted as the bar graph was performed using one-way analysis of variance, repeated (related) measures with Tukey's multiple comparison post-tests. Adjusted \*\**P* \< 0.01; \*\*\**P* \< 0.001; ns, not significant.](mol.118.111948f4){#F4}

### Functional Cooperativity of Cmpd-6 with Transducers at the *β*~2~AR. {#s24}

Our data from the cellular assays ([Fig. 2](#F2){ref-type="fig"}) strongly support the PAM activity of Cmpd-6 and suggest a functional cooperativity between the compound and the transducers Gs and *β*-arrestin. To confirm this cooperative property of Cmpd-6, we performed competition radioligand binding on membrane preparations expressing *β*~2~AR or its C-terminal fusions with the transducer, Gs*α* ([Fig. 5, A and B](#F5){ref-type="fig"}) or *β*-arrestin1 (a.k.a arrestin2) ([Fig. 5, C and D](#F5){ref-type="fig"}). Compared with *β*~2~AR alone, both transducer fusions revealed the expected high-affinity coupling to the receptor with a left shift in ISO dose--response curves. Importantly, addition of Cmpd-6 at *β*~2~AR fusions enhanced both Gs*α*- and *β*-arrestin1--mediated high-affinity coupling to the receptor and also resulted in a significant potentiation of ISO affinity compared with uncoupled receptor ([Fig. 5, B and D](#F5){ref-type="fig"}). Additionally, we assessed the PAM activity of Cmpd-6 by measuring binding of the radiolabeled orthosteric agonist ^3^H-FEN aimed at saturating high-affinity sites on the *β*~2~AR ([Fig. 5, E and F](#F5){ref-type="fig"}). Compared with no transducer controls, addition of Cmpd-6 or the exogenous transducers, heterotrimeric Gs (at *β*~2~AR membranes; [Fig. 5E](#F5){ref-type="fig"}) and *β*-arrestin1 (at phosphorylated *β*~2~V~2~R membranes; [Fig. 5F](#F5){ref-type="fig"}), robustly increased the high-affinity ^3^H-FEN binding to the receptor. Interestingly, addition of Cmpd-6 together with Gs or *β*arrestin1 further enhanced the maximal high-affinity ^3^H-FEN binding. Although there was noticeable cooperativity between Cmpd-6 and Gs, this potentiation in ^3^H-FEN binding was also prominent in the presence of the G protein mimic Nb80 ([@B29]) ([Supplemental Fig. 4A](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)). Together with our findings from cellular assays, these binding studies clearly demonstrate a positive cooperativity between Cmpd-6 and transducers to modulate high-affinity state agonist binding to the *β*~2~AR.

![Positive allosteric cooperativity of Cmpd-6 for transducer-induced activities at the *β*~2~AR. (A--D) Data showing positive cooperativity of Cmpd-6 (20 *µ*M) assessed by ^125^I-CYP versus (ISO) competition binding at membrane preparations from HEK cells overexpressing *β*~2~AR or the transducer fusions *β*~2~AR-Gs*α* (A) and *β*~2~V~2~R-*β*-arrestin1 (*β*arr1) (B). Points on the curves represent normalized cpm values from three independent experiments, expressed as two-site curve fit with shared IC~50Low~ (GraphPad Prism). Associated bar graphs show Cmpd-6--mediated fold changes in ISO affinity at *β*~2~AR-Gs*α* (B), and *β*~2~V~2~R-*β*arr1 (D) fusions, respectively, expressed as a ratio of IC~50Low~/IC~50High~. (E and F) ^3^H-FEN saturation-binding curves showing Cmpd-6--mediated potentiation ^3^H-FEN binding at Sf9 cell membranes expressing the *β*~2~AR (E) and in cells expressing the phosphorylated *β*~2~V~2~R (F). Points on the curves represent cpm values normalized to the maximal level mediated by Gs (E) or *β*arr1 (F), respectively. DMSO (0.2%) was included as vehicle control in respective experiments for conditions without Cmpd-6. Values indicate mean ± S.D. from at least three independent experiments. Statistical analyses for the results depicted as the bar graphs (B and D) as well as Bmax changes in (E and F) were performed using one-way analysis of variance, repeated (related) measures with Tukey's multiple comparison post-tests. Adjusted \**P* \< 0.05; \*\**P* \< 0.01.](mol.118.111948f5){#F5}

Of note, the data in [Supplemental Fig. 4A](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1) also suggest that Cmpd-6 does not occlude transducer coupling to the *β*~2~AR and most likely binds to a potentially unique allosteric site in the receptor. Accordingly, to test whether Cmpd-6 physically competes for binding to the intracellular transducer-binding pocket, we performed an enzyme-linked immunosorbent assay to capture the *β*~2~AR with the G protein mimic Nb80 that recognizes agonist-bound active state of the receptor ([Supplemental Fig. 4B](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)). In the presence of the high-affinity agonist BI-167107, and compared with DMSO or the antagonist ICI-118551, there was a marked increase in receptor capture by Nb80. This receptor capture was significantly inhibited in the presence of saturating amounts of a competing nanobody Nb6B9 ([@B30]), which is an affinity-matured version of Nb80 and thus competes for a common binding epitope on the *β*~2~AR. Interestingly, and in contrast to Nb6B9, under these experimental conditions the addition of a saturating concentration of Cmpd-6 did not alter the capture of *β*~2~AR by Nb80. These data suggest that presence of Cmpd-6 does not interfere with transducer coupling to the *β*~2~AR, which further establishes positive cooperativity between transducers and the compound.

### The PAM Activity of Cmpd-6 Is Specific for the *β*~2~AR. {#s25}

The specificity of Cmpd-6 for the *β*~2~AR was first evaluated through in vitro competition radioligand (^125^I-CYP) binding at the *β*~1~AR, the most closely related subtype of the adrenoceptor. In this assay, Cmpd-6 induces a minimal left shift of the ISO competition curve for binding to the *β*~1~AR ([Supplemental Fig. 5A](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)) unlike the robust ISO curve shift by Cmpd-6 observed with the *β*~2~AR ([Fig. 3A](#F3){ref-type="fig"}). This shows that Cmpd-6 specifically induces the high-affinity binding of the orthosteric agonist ISO to the *β*~2~AR, but not to the *β*~1~AR. Furthermore, we observed only marginal changes promoted by Cmpd-6 in the ISO dose--response pattern of *β*~1~AR-mediated cAMP production ([Supplemental Fig. 5B](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)), which is markedly different from that of the *β*~2~AR-mediated response ([Supplemental Fig. 2](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)). We also detected minimal allosteric effects of Cmpd-6 on cAMP production mediated by other receptors. These are the transiently overexpressed V~2~R ([Supplemental Fig. 5C](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)), as well as the prostaglandin E~2~ ([Supplemental Fig. 5D](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)) and the vasoactive intestinal peptide ([Supplemental Fig. 5E](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)) receptors, both endogenously expressed in the assay cells. These findings clearly demonstrate that the PAM activity of Cmpd-6 is specific for the *β*~2~AR relative to the *β*~1~AR and other receptors tested in this work.

### PAM Activity of Cmpd-6 When the *β*~2~AR Is Stimulated with a Range of Different Agonists. {#s26}

Some allosteric modulators show differential activity depending on the orthosteric agonist stimulating the receptor, a phenomenon known as probe dependence ([@B42]; [@B8]). We examined whether Cmpd-6 displays such differential activity when the orthosteric site of the *β*~2~AR is occupied with a range of agonists, namely epinephrine (EPI) and fenoterol (FEN), which are very strong partial agonists compared with ISO, and clenbuterol (CLEN), which is a weak partial agonist ([@B27]). We first evaluated the extent of the dose--response curve (IC~50~ value) shift induced by Cmpd-6 in radioligand (^125^I-CYP) competition binding to the *β*~2~AR ([Supplemental Fig. 6, A--D](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)). This allowed us to test the allosteric activity of Cmpd-6 solely for binding of an agonist in the absence of transducer coupling to the receptor. We observed that the extent of the curve shift in the presence of Cmpd-6 in this assay essentially followed the efficacy of the tested agonists to induce downstream signaling.

We next compared the PAM activity of Cmpd-6 for downstream signaling of the *β*~2~AR when stimulated with these four agonists using cell-based functional assays, monitoring cAMP accumulation ([Supplemental Fig. 6, E--H](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)) and *β*-arrestin2 recruitment to the receptor ([Supplemental Fig. 6, I--L](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)). In general, full and strong partial agonists show greater affinity (EC~50~ value) shifts by Cmpd-6 compared with that observed with the weak partial agonist CLEN. However, CLEN displayed a substantially greater Cmpd-6--mediated increase in maximal response than did the full agonists. Interestingly, no direct relationship between the extent of the EC~50~ shift by Cmpd-6 and the efficacy of ISO, EPI, and FEN was seen. In functional assays, Cmpd-6 induced a noticeably greater shift with EPI ([Supplemental Fig. 6, F and J](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)) than with ISO ([Supplemental Fig. 6, E and I](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)) and FEN ([Supplemental Fig. 6, G and K](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.111948/-/DC1)), whereas the fold increases by Cmpd-6 in the maximal response induced by these agonists were comparable. Thus, we did not observe any unique probe dependence of Cmpd-6 with this small panel of agonists.

### Structure--Activity Relationships of Cmpd-6 Analogs. {#s27}

To determine structure--activity relationships (SAR) around Cmpd-6, a rational design approach and synthesis of a series of Cmpd-6 analogs ([Table 1](#T1){ref-type="table"}) were carried out. We evaluated the allosteric effect of these derivatives on orthosteric agonist ^3^H-FEN binding to the *β*~2~AR in the absence and presence of transducers, either trimeric Gs protein or *β*-arrestin1. We also tested them for their allosteric activity in ISO-stimulated *β*~2~AR downstream signaling, that is G protein--mediated cAMP production and *β*-arrestin2 recruitment to the activated receptor. For convenience of presenting the SAR analyses, Cmpd-6 and its analogs have been broken down into a common core scaffold, 5-hydrosulfonyl-2-mercaptobenzaldehyde (black), and three diverse substituents (R): N-methylpropan-2-amine (R1, blue), 4-methoxy-benzene (R2, red), and (R)-3-amino-4-(4-(*tert*-butyl)phenyl) butanamide (R3, purple). The R1 region is common in this subset of analogs although varying in the initial analogs from the screening, as shown in [Fig. 1B](#F1){ref-type="fig"}. The main focus of this initial analog series was to probe the importance of modifications at the R2 and R3 positions of Cmpd-6; these modifications are shown in [Table 1](#T1){ref-type="table"}. When the whole R3 portion of Cmpd-6 was replaced with a much smaller *piperidine* moiety as in analog A3, the PAM activity of Cmpd-6 was abolished, indicating that the bulkiness imparted by the *tert*-butyl at this region of the molecule is critical for the PAM activity of the compound. Further exploration of the relationship between activity and structure at R3, achieved by replacing the 4-*tert*-butyl on the benzene ring with 4-OH, and the amide tail with carboxyl as in analog A6, as well as with 4-H as in analog A7, revealed the importance of the large lipophilic ring system for the activity of Cmpd-6. This was more evident with the highly polar analog A6, which was considerably less active than the original compound, whereas the relatively small, but lipophilic, analog A7 showed moderate activity. SAR around R2 also showed significant decreases in the PAM activity of Cmpd-6, when its electron-donating group 4-OCH~3~ was replaced with an electron-withdrawing 4-OCF~3~ group at its *para* position to yield analog A4. Interestingly, when the *para*-OCH~3~ group in Cmpd-6 was replaced with a *meta*-OCH~3~ substitution, as in A5, there was a moderate decrease in the PAM activity of Cmpd-6. The results from these two analogs suggest that there may be a polar interaction, like H-bonding type, located in the area surrounding this 4-position of R2, which interacts with the putative binding site on the *β*~2~AR.

###### 

Structure--activity relationships of Cmpd-6 analogs

Different chemical scaffolds in the R2 and R3 regions between Cmpd-6 and its analogs are illustrated. Changes in the Vmax value by Cmpd-6 or each analog at 32 *μ*M are expressed as percentages of the maximal level of the ISO-induced activity in the vehicle (DMSO) control in each assay. Changes in the EC~50~ value are expressed as fold shifts compared with the control value obtained in the vehicle (DMSO)-treated curve in each assay. Every value represents mean ± S.D. obtained from four independent experiments done in duplicate. Statistical analyses were performed using one-way analysis of variance with Dunnett's multiple comparison post-tests compared with the control Cmpd-6--treated value in each assay. Adjusted \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.
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Rc, receptor.

Discussion {#s28}
==========

In the present study, DEL screening with the agonist-occupied *β*~2~AR in HDL particles has yielded the first small-molecule PAMs for the *β*~2~AR. We had isolated a small-molecule *β*~2~AR NAM, Cmpd-15, from a previous screening ([@B1]), but until now no PAM small molecule for this receptor had been described. Among these isolated PAM molecules, the most efficacious one, Cmpd-6, was characterized in detail through multiple assays. Cmpd-6 has a low micro-molar binding affinity for the agonist-occupied *β*~2~AR and displays potent PAM activity for this receptor. Cmpd-6 positively cooperates with *β*~2~AR agonists to enhance downstream signaling responses such as cAMP production and *β*-arrestin recruitment to the receptor. It not only potentiates the affinity (EC~50~ values) of agonists for these responses, but also increases the agonist-induced maximal level of the responses. This is in agreement with pharmacological studies wherein Cmpd-6 shows positive cooperativity with transducers in mediating the agonist-bound high-affinity state of the *β*~2~AR. Furthermore, Cmpd-6 stabilizes the agonist-induced active conformation of the *β*~2~AR, leading to potentiation of the agonist-binding affinity for the receptor, which is a hallmark of PAMs ([@B19]; [@B42]; [@B8]). Although Cmpd-6 does not show unique probe dependence or obvious biased activity toward either G protein or *β*-arrestin signaling, it clearly displays a ceiling effect for its activity, another pharmacological characteristic of PAMs ([@B42]; [@B8]). As expected for a PAM, Cmpd-6 also shows strong specificity for the *β*~2~AR relative to the *β*~1~AR and other receptors tested in this study. It only minimally potentiates the binding affinity of agonists to the *β*~1~AR, as well as *β* agonist--induced downstream functional activity.

Through a set of Cmpd-6 derivatives, we were able to discern the SAR patterns of the positive allosteric modulation of *β*~2~AR agonist activities and where the potential pharmacophore regions of the compound might be. As is apparent from our SAR studies, the *N*-isopropyl-*N*-methyl group is the preferred substituent at the R1 position attached to the common core chemical scaffold, 5-hydrosulfonyl-2-mercaptobenzaldehyde. At this region, bulkier groups such as *N*-cyclopentyl and *N*-phenyl result in increasingly poor PAM activity. At the R2 position, an electron-donating methoxy group, in the *para* position on the phenyl ring, is favored. This suggests that there may be a polar interaction involving the methoxy functional group at the R2 position that interacts with the amino acid residues of the *β*~2~AR site. In the case of the R3 position, our analysis indicates that bulky and hydrophobic groups, such as *tert*-butyl benzene chemical scaffolds, are favored. This finding therefore suggests that this region of the molecule may occupy a hydrophobic pocket, deep within a putative *β*~2~AR allosteric binding site to establish contacts with core hydrophobic residues. Solution of an X-ray crystallographic structure of the *β*~2~AR in complex with Cmpd-6 will provide further insights into the binding modes of the compound.

Because allosteric ligands are able to freeze or lock receptors into specific conformations by virtue of their cooperative interactions with orthosteric ligands, they can facilitate the study of receptors by biophysical techniques. Recently, atomic-level structural features of several GPCRs occupied by their allosteric ligands have been elucidated through X-ray crystallographic analyses ([@B18]; [@B45]; [@B14]; [@B26]; [@B46]; [@B22]; [@B38]). Such biophysical studies have revealed mechanisms by which allosteric ligands modulate the binding and action of orthosteric ligands. To date, most of the solved GPCR crystal structures together with allosteric ligands have been achieved with allosteric antagonists (or NAMs). An X-ray crystallographic study of the M2 muscarinic acetylcholine receptor (mAChR) occupied by its high-affinity orthosteric agonist and PAM, in a complex together with a transducer mimic nanobody, is the only case previously reported with a PAM ([@B18]). Therefore, it will be of great interest to obtain atomic-level information with the Cmpd-6--occupied *β*~2~AR to determine how the compound positively cooperates with orthosteric agonists. Such studies will expand our understanding on the mechanistic details, by which PAMs exert their effects on GPCRs.

Cmpd-6 and its analogs are the first small-molecule PAMs for the *β*~2~AR. To date, several PAM molecules have been isolated for some other GPCRs ([@B8]; [@B12]). These include, for example, small molecules for different subtypes of mAChRs, namely benzyl quinolone carboxylic acid for the M1 mAChR ([@B6]) and LY2033298 for the M2 and M4 mAChRs ([@B7]; [@B18]); 4-(3-benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine for the glucagon-like peptide-1 receptor ([@B43]); and VCP171 \[2-amino-4-(3-(trifluoromethyl)phenyl)(thiophen-3-yl)(phenyl)methanone\] for the adenosine A1 receptor ([@B2]). Among others, cinacalcet, which is a PAM for the calcium-sensing receptor, is currently used as a therapeutic drug for hyperparathyroidism ([@B21]). Likewise, Cmpd-6 or its analogs may have potential to serve as lead molecules for the development of new therapeutic drugs for *β*~2~AR-related diseases. Cmpd-6 has strong specificity for the *β*~2~AR (found predominantly in smooth muscle) over the most closely related, cardiac-specific subtype *β*~1~AR. Its activity also has a clear ceiling level, which can reduce risks from target-based overdoses. As an allosteric modulator, when used in a therapeutic context, Cmpd-6 will only exert its modulating activity when an endogenous agonist of the *β*~2~AR, e.g., epinephrine, is available. Altogether, PAMs such as Cmpd-6, which can fine-tune the activity of the *β*~2~AR, hold great potential for the development of better therapeutic treatments for diseases like asthma, for which the clinical use of current *β*AR agonists is limited by adverse side effects ([@B24]).

The present study yielding PAMs, together with our previous work isolating a NAM ([@B1]), strongly demonstrates that our current DEL screening approach with purified GPCRs can be used to accomplish target conformation-specific selection through in vitro manipulation of the receptors. Accordingly, we successfully isolated a NAM using the unoccupied *β*~2~AR in an inactive conformation, but obtained PAMs using the high-affinity agonist-occupied receptor in active conformations. In the future, complexes of the receptors with transducers G protein and *β*-arrestin, which are also allosteric molecules, could be used to isolate allosteric molecules that might have even more unique biased functional profiles.

In conclusion, in this study we introduce the discovery of the first small-molecule PAMs for the *β*~2~AR through an in vitro affinity-based iterative selection of highly diverse DELs against the agonist-occupied receptor in HDL particles. Characterization of the strongest PAM among these molecules reveals its positive cooperativity with orthosteric agonists in a wide range of receptor functions and its high selectivity for the *β*~2~AR. A number of pharmacological features of this compound suggest potential advantages of such a PAM over orthosteric agonists as a therapeutic drug. Finally, our current findings, together with our previous isolation of the first *β*~2~AR NAM ([@B1]), establish a proof-of-concept strategy to isolate allosteric molecules with tailored functional profiles.
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